PofoliaShared via Pofolia

Hepatology Research· 2026Q1

Trends in the Proportion of Hepatitis C Virus Antibody‐Positive Patients Who Could be Considered for Direct‐Acting Antiviral Therapy Identified Through Preoperative Testing for Ophthalmic Surgery: A Nationwide Multicenter Real‐World Cohort Study in Japan

Ritsuzo Kozuka, Yoshihito Uchida, Hatsue Fujino, Akira Asai et al.

Short summary

A nationwide study in Japan found that between 28.4% and 44.4% of Hepatitis C Virus (HCV) antibody-positive patients identified through preoperative ophthalmic surgery testing were eligible for direct-acting antiviral (DAA) therapy from 2019-2023.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Sign in on the web to open

Field: Hepatology

HepatologyMedicine